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Abstract
OBJECTIVE—To compare perinatal outcomes between self-identified Hispanic and non-
Hispanic white women with mild gestational diabetes mellitus (GDM) or glucose intolerance.
METHODS—In a secondary analysis of a mild GDM treatment trial, we compared perinatal
outcomes by race and ethnicity for 767 women with glucose intolerance (abnormal 50g 1-hour
screen, normal 100g 3-hour oral glucose tolerance test [OGTT]), 371 women with mild GDM
assigned to usual prenatal care, and 397 women with mild GDM assigned to treatment. Outcomes
included: composite adverse perinatal outcome (neonatal death, hypoglycemia,
hyperbilirubinemia, hyperinsulinemia; stillbirth; birth trauma), gestational age at delivery,
birthweight, and hypertensive disorders of pregnancy. Adjusted regression models included: 100g
3-hour OGTT results; parity; gestational age, body mass index, maternal age at enrollment; and
current tobacco use.
RESULTS—The sample of 1535 women was 68.3% Hispanic and 31.7% non-Hispanic White.
Among women with glucose intolerance, Hispanic women had more frequent composite outcome
(37% vs. 27%, aOR 1.62 95%CI 1.10, 2.37), with more neonatal elevated C-cord peptide (19% vs.
13%, aOR 1.79 95%CI 1.04, 3.08) and neonatal hypoglycemia (21% vs. 13%, aOR 2.04 95%CI
1.18, 3.53). Among women with untreated mild GDM, outcomes were similar by race/ethnicity.
Among Hispanic women with treated mild GDM, composite outcome was similar to non-Hispanic
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White women (35% vs. 25%, aOR 1.62 95% CI 0.92, 2.86), but Hispanic neonates had more
frequent hyperinsulinemia (21% vs. 10%, aOR 2.96 95%CI 1.33, 6.60).
CONCLUSION—Individual components of some neonatal outcomes were more frequent in
Hispanic neonates, but most perinatal outcomes were similar between Hispanic and non-Hispanic
ethnic groups.
Introduction
Gestational diabetes (GDM) complicates 4–7% of all pregnancies, and its prevalence
continues to rise in parallel with the evolving obesity epidemic.(1) Hispanic women in the
United States have a higher prevalence of GDM compared with Caucasian or African-
American women.(2–5) Across racial/ethnic groups, hyperglycemia increases risks of
adverse perinatal outcomes, including large for gestational age (LGA), shoulder dystocia,
cesarean delivery, and hypertensive disorders of pregnancy.(6, 7) Strict glycemic control
decreases risks of these outcomes.(8)
Whether the risk of adverse outcomes associated with mild GDM differs by race/ethnicity,
however, is less clear. Among those without GDM, Hispanic women experience lower
neonatal mortality, are less likely to deliver low birthweight infants,(9, 10) and have had a
lower reported prevalence of pre-eclampsia, compared with Caucasians and African-
Americans.(11) While some data suggest adverse outcome risk may also vary by race/
ethnicity among women with GDM,(5, 12–14) findings are not consistent. . Thus, whether
differences are specific to GDM or related to race/ethnicity independent of hyperglycemia is
uncertain.
To address this uncertainty, we analyzed a large cohort of women with glucose intolerance,
and untreated and treated mild GDM, but not overt diabetes of pregnancy, and measured
differences in perinatal outcomes by race/ethnicity.
Materials and Methods
We performed a secondary analysis of the Eunice Kennedy Shriver National Institute of
Child Health and Human Development (NICHD) Maternal-Fetal Medicine Units (MFMU)
Network multi-site randomized clinical trial for the treatment of mild GDM(15) and
compared perinatal outcomes by self-reported race/ethnicity. We compared women self-
reported as Hispanic (including Mexican-American, Central/South American, or Caribbean)
with women self-reported as White (and not Mexican-American, Central/South American,
or Caribbean). A total of eight women self-reported their race/ethnicity as Hispanic as well
as: African-American or Native American/Alaskan; these eight women were included in the
Hispanic group.
Women were eligible if they had a 1-hour 50-g glucose load test result between 135 and 200
mg/dL between 24 0/7 weeks and 30 6/7 weeks’ gestation. They were excluded if they had
pre-gestational diabetes; an abnormal glucose screening test prior to 24 weeks’ gestation; a
history of GDM, stillbirth, multi-fetal gestation, asthma, or chronic hypertension; if taking
corticosteroids; or if imminent preterm delivery was anticipated. The original study sample
and randomization process has been further described previously.(15) In initial
randomization, eligible women with an elevated 50g 1-hr glucose load result underwent a
100g 3-hr OGTT, and these results diagnosed mild GDM. Women were randomized to
treatment vs. no treatment, matched for race/ethnicity and body mass index (BMI < vs. > 27
mg/kg2). Women with normal OGTT results were enrolled as the observational cohort. The
primary composite adverse perinatal outcome for the original study was occurrence of one
or more of the following: perinatal mortality (stillbirth or perinatal death), hypoglycemia,
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hyperbilirubinemia, elevated cord blood C-peptide level, or birth trauma.(15) The sample
size for the current study was constrained by the sample size of the original trial. The
original study was approved by the institutional review board at each participating center,
and all participating women provided written informed consent.
A total of 1889 women were enrolled in the original study, including 1535 who were either
Hispanic and non-Hispanic White. These 1535 women were classified into one of three
groups in the parent study: 1) 767 women with glucose intolerance with an elevated 50g 1-
hour screening test (≥135, but <200 mg/dL) but normal 3-hour oral glucose tolerance test
(OGTT), matched to the randomized patients by clinical center, race/ethnicity, and body
mass index (BMI); 2) 371 women with mild GDM as diagnosed by a fasting glucose <95
mg/dL but two or more 100g 3-hour oral glucose tolerance test (OGTT) results at or above
established thresholds(16) who were randomized to no treatment; and 3) 397 women also
diagnosed with mild GDM by the same criteria as above but who were randomized to
treatment. Women were randomly assigned to no treatment versus treatment (nutritional
counseling and diet therapy, with insulin if required) by simple urn method(17) as
previously described.(15)
We report overall and individual components of the composite outcome: hyperbilirubinemia,
elevated cord blood C-peptide, and hypoglycemia. Perinatal mortality and birth trauma are
not included in individual analyses due to small numbers for each.(15) We also evaluated
gestational age at delivery (weeks’ gestation, preterm birth <37 weeks), birthweight (grams,
small for gestational age, large for gestational age, macrosomia >4000g), either gestational
hypertension or pre-eclampsia, and neonatal intensive care unit (NICU) admission.
Identification of large for gestational age used growth standards that accounted for race and
Hispanic ethnicity, as in the original study.(18) Study personnel abstracted pertinent data for
enrolled women and their newborns at time of hospital discharge.
We compared baseline demographic characteristics and perinatal outcomes by Hispanic
versus non-Hispanic White race/ethnicity. We used Student’s t-test for continuous variables
and chi-square or Fisher’s exact test for categorical variables. For each perinatal outcome,
we performed multiple linear or logistic regression analysis for continuous and categorical
outcomes, respectively. All adjusted models included: fasting, 1, 2, and 3-hour results of 100
g 3-hour OGTT; parity; gestational age at enrollment; pre-pregnancy body mass index;
maternal age at enrollment; and tobacco use in current pregnancy.
Statistical analyses were conducted with SAS software (SAS Institute, Cary, NC). A
nominal two-sided P value less than 0.05 was considered to indicate statistical significance
and no adjustments were made for multiple comparisons.
Results
Our sample of 1535 women was 68.3% Hispanic and 31.7% non-Hispanic White. Race/
ethnicity was similar (p=.90) among the three cohorts. Hispanic and non-Hispanic White
women in the treated mild GDM cohort were equally likely to receive insulin (1.2% vs.
2.3%, p=0.09).
Demographic characteristics by race/ethnicity are shown in Table 1. Results of GDM
screening (50g 1-hour glucose load) and diagnostic (100g 3-hour oral OGTT) tests are
shown in Table 2. For all three cohorts, 50 g 1-hour oral glucose load results were similar by
ethnicity. In the glucose intolerant cohort, Hispanic women had higher 100g 3-hour OGTT
results at 1 hour (156.3 vs. 151.2 mg/dL, p=0.006) and 3 hours (111.6 vs. 105.3 mg/dL,
p=0.0002). In the untreated mild GDM cohort, Hispanic women had higher 100g 3-hour
OGTT results at 3 hours (136.7 vs. 128.6 mg/dL, p=0.02). In the treated mild GDM cohort,
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Hispanic women had greater 100g 3-hour OGTT results at time of fasting (86.9 vs. 85.5 mg/
dL, p=0.04) and 100g 3-hour OGTT results at 3 hours (140.3 vs. 133.3 mg/dL, p=0.02).
Results for women in the glucose intolerant cohort are shown in Table 3. Hispanic women
had more frequent composite perinatal outcome. The observed increased risk of composite
perinatal outcomes among Hispanic neonates is driven by their increased risk of
hyperinsulinemia and hypoglycemia. Gestational age at delivery was greater among
Hispanic women, but mean gestational age was greater than 39 weeks for both groups. Other
secondary perinatal outcomes were similar.
Results for women with untreated mild GDM are shown in Table 3. Non-Hispanic White
and Hispanic women had similar prevalence of the composite perinatal outcome and each of
the three reported outcome components is similar between groups. As in the glucose
intolerant cohort, Hispanic women with untreated mild GDM delivered at a greater
gestational age, but this difference was less than four days. Other secondary outcomes were
similar between groups.
Results for women in the treated mild GDM cohort are shown in Table 3. Composite
neonatal outcome prevalence did not differ between groups. The 10% greater prevalence of
the composite outcome, equal to the prevalence difference in the glucose intolerant cohort, is
driven by the increased risk of elevated cord C-peptide among Hispanic women. As in the
other two cohorts, Hispanic women with untreated mild GDM delivered at a greater
gestational age, but this difference was less than four days. Other secondary outcomes were
equally likely between groups.
Mexican-American women comprised 75% of all women classified as Hispanic. Significant
differences in the composite outcome reported among all Hispanic women, compared with
non-Hispanic White women, remained significant when only Mexican-American women
were compared to non-Hispanic White women. Outcomes among the smaller subsets of
Central or South American women and Caribbean women, also classified as Hispanic,
compared with non-Hispanic White women, were not different.
Discussion
Among women with glucose intolerance and with treated or untreated mild GDM, Hispanic
neonates were more likely to experience adverse neonatal outcomes, although not in a
uniform pattern, and maternal outcomes did not differ by race/ethnicity. Our data do not
support racial/ethnic tailored diagnostic thresholds, as suggested in reports of women with
overt GDM.
Our findings differ from other published data that illustrate the Hispanic Paradox, a term to
describe the better-than-expected outcomes among a socioeconomically disadvantaged
racial/ethnic group, more likely to live in poverty than their non-Hispanic White
counterparts, and more similar to African-American than non-Hispanic populations.(19)
While GDM prevalence is higher among Hispanic women, other important outcomes such
as low birthweight remain lower.(20–22) Others(3, 11, 14, 23) have reported on the
differences in hyperglycemia-associated adverse outcomes among infants of Hispanic
women with GDM, when compared with other races/ethnicities.
Results have been inconsistent. One report found that, when compared with Caucasian
women, Hispanic women were more likely to achieve glycemic control with diet alone in
one large cohort.(14) Data from another large cohort reported that Hispanic women were
more likely to require medical management of their GDM.(23) Hispanic women in the latter
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cohort had less frequent hypertensive disorders of pregnancy and fewer preterm births, but
more frequent shoulder dystocia, when compared with Caucasian women.
Retrospective analyses without a non-GDM group or groups with varying degrees of
hyperglycemia have limitations. Inconsistent differences in adverse outcomes by race/
ethnicity may be specific to GDM pathophysiology or mechanisms of insulin resistance, as
has been proposed. A recent analysis of statewide birth certificate data suggested the effect
size of racial/ethnic differences in outcomes among GDM are not large enough to support
racial/ethnic specific GDM diagnosis and treatment thresholds.(24) Our results support this
conclusion, and our analysis was able to overcome some limitations of these prior studies.
A primary strength of our study was our ability to evaluate racial/ethnic differences among
women with mild hyperglycemia. These women are at increased risk of adverse outcomes
but not diagnosed or treated by current diagnostic thresholds. The randomization of women
with mild GDM in the original trial allowed us to evaluate racial/ethnic differences in
women who are treated and not treated. A cohort of women with glucose intolerance but no
GDM allowed us to compare racial/ethnic differences even among women with
hyperglycemia below the most inclusive thresholds warranting treatment. As only women in
the treated mild GDM cohort were eligible for insulin and the overall proportion of women
receiving insulin was low and similar by race/ethnicity, treatment type did not likely bias our
results. Finally, a large sample size and rigorously collected prospective data allowed us to
examine several relative perinatal outcomes and consider multiple potential confounders in
adjusted analyses.
This secondary analysis also has limitations. While our study population was over two-thirds
Hispanic, it remains a heterogenous group, and data on women’s culture of origin are
limited. Length of time in the United States and acculturation, measured by English
proficiency, may minimize the paradoxical improved health seen in Hispanic women.(9, 22)
Our data did not include measures of acculturation, so we were unable to evaluate this
potential confounder. While our reported statistical differences only persist when Mexican
women are compared with non-Hispanic White women, this is likely due to small numbers
of women from other countries. Without adequate numbers to power such a sub-analysis,
these data are exploratory only. Larger numbers of South or Central American or Caribbean
women would be required to evaluate these differences.
In addition, the primary trial was not powered to the outcomes used in this secondary
analysis, and lack of statistical significance may represent a beta error. For example, the
difference in primary composite outcome is significant by race/ethnicity in the glucose
intolerant groups. However, while the prevalence of this outcome is mirrored among
Hispanic and non-Hispanic White women in the treated mild GDM cohort, this is not
statistically significant.
Despite these limitations, this secondary analysis of a large, prospective, randomized
controlled trial of mild GDM demonstrates that most perinatal outcomes were similar
between Hispanic and non-Hispanic ethnic groups. Only individual components of neonatal
outcomes were more frequent in Hispanic neonates.
Growing support to implement more inclusive GDM diagnostic criteria will further increase
GDM prevalence. A substantial proportion of women will still have some degree of
hyperglycemia but not be diagnosed and treated for GDM. The overall high prevalence of
adverse outcomes among these women without overt GDM, however, highlights an area for
research. Additional efforts may target at-risk women with hyperglycemia, but not overt
GDM, for intervention and treatment, regardless of race/ethnicity. Our findings suggest that
diagnostic criteria tailored to race/ethnicity may not be warranted, at least not among women
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with mild GDM or glucose intolerance. If tailored treatment to optimize glycemic control
among Hispanic women are pursued, we would suggest using specific neonatal diagnoses –
such as C-cord peptide or neonatal hypoglycemia - as study outcomes.
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